AstraZeneca PLC AZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE US (9502L)

TIDMAZN

RNS Number : 9502L

AstraZeneca PLC

07 October 2016

This announcement contains inside information

7 October 2016 07:00

ASTRAZENECA ENTERS AGREEMENT WITH

CILAG GMBH INTERNATIONAL TO DIVEST RIGHTS TO RHINOCORT AQUA

OUTSIDE THE US

AstraZeneca today announced that it has entered into an agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US.

Rhinocort Aqua is a nasal spray indicated for allergic and non-allergic rhinitis (inflammation of the inside of the nose), and for the treatment of nasal polyps (swelling of the nasal lining). The active ingredient is the anti-inflammatory medicine budesonide.

Mark Mallon, Executive Vice President, Global Product & Portfolio Strategy at AstraZeneca, said: "This agreement allows us to concentrate our efforts in Respiratory as one of our three strategic therapy areas, on transforming the treatment of asthma and COPD, where budesonide remains a key component of our marketed as well as pipeline medicines."

Financial considerations

The agreement is subject to customary closing conditions and is expected to complete in the fourth quarter of 2016. As AstraZeneca will not maintain a significant ongoing interest in Rhinocort Aqua, the $330 million payment received from Cilag GmbH International upon completion of the transaction will be recognised as Other Operating Income in the Company's financial statements. The transaction does not include the transfer of any AstraZeneca employees or facilities and does not impact the Company's financial guidance for 2016.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory, Cardiovascular & Metabolic Diseases, and Oncology. The Company is also selectively active in Neuroscience and Autoimmunity. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

 
 Media Enquiries 
 Neil Burrows          UK/Global                [phone] 
 Vanessa Rhodes        UK/Global                [phone] 
 Karen Birmingham      UK/Global                [phone] 
 Rob Skelding          UK/Global                [phone] 
                                                [phone] 
 Jacob Lund            Sweden                    20 
 Michele Meixell       US                       [phone] 
 Investor Relations 
 UK 
 Thomas Kudsk 
  Larsen                                        [phone] 
                       Finance, Fixed           [phone] 
 Craig Marks            Income, M&A              764 
 Nick Stone            Respiratory              [phone] 
 Henry Wheeler         Oncology                 [phone] 
                       Neuroscience 
 Christer Gruvris       & Autoimmunity          [phone] 
 US 
                       Cardiovascular 
 Lindsey Trickett       & Metabolic Diseases    [phone] 
 Mitchell Chan          Oncology                [phone] 
 Toll-free                                      [phone] 
 

Adrian Kemp

Company Secretary

AstraZeneca PLC

-ENDS-

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRAKADKNBDBBKK

(END) Dow Jones Newswires

October 07, 2016 02:00 ET (06:00 GMT)